Leading Industry Participants Reinforce Their Standing in the Oligonucleotide Therapy Market

The oligonucleotide therapy market is set to experience significant expansion in the coming years, driven by advances in personalized medicine and innovative drug development techniques. This sector is rapidly evolving, backed by increased collaborations and technological breakthroughs that are shaping its future trajectory. Below, we explore the projected market valuation, key players, emerging trends, and important market segments.

Forecasted Market Valuation of the Oligonucleotide Therapy Market by 2030
The oligonucleotide therapy market is projected to grow substantially, reaching a valuation of $10.87 billion by 2030. This represents a compound annual growth rate (CAGR) of 12.0% over the forecast period. Factors contributing to this strong growth include the expansion of personalized medicine approaches, the integration of artificial intelligence in drug discovery processes, progress in precision medicine initiatives, the creation of next-generation delivery platforms, and heightened partnerships between biotechnology and pharmaceutical companies. Key trends expected to influence the market include targeted gene regulation, RNA interference-based therapies, advancements in personalized medicine, innovative drug delivery methods, and developments in nucleic acid-based diagnostic tools.

Download a free sample of the oligonucleotide therapy market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3398&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Leading Companies Driving the Oligonucleotide Therapy Market
Several major corporations are at the forefront of the oligonucleotide therapy industry. These include Pfizer Inc., GlaxoSmithKline plc, Gilead Sciences Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., SomaGenics Inc., Wave Life Sciences Ltd., Exicure Inc., Avidity Biosciences Inc., Miragen Therapeutics Inc., ProQR Therapeutics NV, Regulus Therapeutics Inc., Kastle Therapeutics LLC, Santaris Pharma A/S, InteRNA Technologies B.V., Evox Therapeutics Ltd., and PepGen Ltd.

Strategic Expansion Moves Within the Market
In April 2025, AlphaRose Therapeutics, a US-based biopharmaceutical firm, announced the acquisition of Alpha Anomeric SA, a France-based company specializing in oligonucleotide therapies. Though financial details were not disclosed, this acquisition is expected to bolster AlphaRose's portfolio of oligonucleotide therapeutics, accelerate innovation in gene-targeted treatments, expand research and development capabilities, and strengthen its global standing in the nucleic acid therapeutics market.

View the full oligonucleotide therapy market report:
https://www.thebusinessresearchcompany.com/report/oligonucleotides-therapy-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Emerging Trends in the Oligonucleotide Therapy Market
The oligonucleotide therapy sector is increasingly focused on the development of advanced therapies such as gene therapy, aimed at correcting the underlying causes of genetic disorders, enhancing patient outcomes, and lowering the long-term burden of treatment. Gene therapies work by delivering functional genes to replace defective or mutated ones within a patient's cells. For example, in June 2023, Sarepta Therapeutics Inc., a US biotechnology company, received FDA approval for ELEVIDYS, a pioneering gene therapy designed for ambulatory pediatric patients with Duchenne muscular dystrophy (DMD). This single-dose treatment delivers a gene encoding a shortened but functional form of dystrophin to muscle cells, targeting the arrest or reversal of disease progression.

Detailed Segmentation of the Oligonucleotide Therapy Market
The oligonucleotide therapy market is categorized into several segments for a comprehensive analysis:
1) By Type: Antisense Oligonucleotide, Aptamer, and Other Types
2) By Application: Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, Kidney Diseases, and Other End-User Areas
3) By End User: Hospitals and Research Institutes

Subcategories include:
- Antisense Oligonucleotide: RNA-Targeted, DNA-Targeted, and Chemically Modified Variants
- Aptamer: DNA Aptamers, RNA Aptamers, and Small Molecule Aptamers
- Other Types: Small Interfering RNA (siRNA), Micro RNA (miRNA), DNAzymes and Ribozymes, and Synthetic Oligonucleotides for Gene Editing

This segmentation highlights the diversity of therapies and application areas within the oligonucleotide market, reflecting its broad potential and continuous innovation.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.